Communiqués Lite Strategy, Inc.

Actions

LITS

US55279B3015

Gestion des placements et exploitants de fonds

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/07/2026			Varia. 5j.	Varia. 1 janv.
0,9765 ^USD	-1,20%		-5,19%	-26,02%

13/05	Lite Strategy, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 mars 2026	CI
17/02	Lite Strategy, Inc. publie ses résultats financiers pour le deuxième trimestre et les six mois clos le 31 décembre 2025	CI

Communiqués

19/06	Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam	GL
18/06	Lite Strategy Leads Strategic Investment in LitVM	GL
13/05	Lite Strategy Reports Fiscal 2026 Third Quarter Results	GL
17/02	Lite Strategy Reports Fiscal 2026 Second Quarter Results	GL
17/11	Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations	GL
29/10/25	Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations	GL
16/10/25	Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026	GL
10/09/25	MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’	BU
05/08/25	MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising	BU
22/07/25	MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange	BU
18/07/25	MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange	BU
13/05/25	MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position	BU
12/02/25	MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position	BU
25/11/24	MEI Pharma : Proxy Statement Form 8 K	PU
14/11/24	MEI Pharma : Reports First Quarter Fiscal Year 2025 Cash Position Form 8 K	PU
12/11/24	MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position	BU
19/09/24	MEI Pharma Reports Fiscal Year End 2024 Cash Position	BU
12/08/24	MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives	BU
22/07/24	MEI Pharma to Consider Strategic Alternatives	BU
09/05/24	MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	BU
12/04/24	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	AQ
11/04/24	MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	BU
11/04/24	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	BU
10/04/24	MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	BU
26/03/24	MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	BU